- Patients
- Clinical Research
- Clinical trials
- KEYNOTE-057 Cohort C
Bladder Cancer
KEYNOTE-057 Cohort C
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
Trial overview
Medical Oncology
Bladder
II
Registration number: NCT02625961. https://clinicaltrials.gov/study/NCT02625961
|
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
(02) 8037 4100 admin.northshore@genesiscare.comMedical Oncologist
Dr Laurence Krieger
MBChB (Hons) FRACP
North Shore
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.